Serum Institute’s 2nd COVID-19 vaccine likely to be launched in September
Serum Institute of India (SII), the world’s greatest Covid-19 vaccine maker, is hopeful of launching its second vaccine for coronavirus — Covovax — by September this 12 months, CEO Adar Poonawalla introduced on Saturday.
“Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India,” stated Adar Poonawalla.
He additional stated that it has been examined in opposition to African and UK variants of Covid-19 and has an total efficacy of 89 per cent. “Hope to launch by September 2021!” the CEO of world’s greatest Covid-19 vaccine maker stated.
Covovax is the protein-based Covid-19 vaccine developed by Novavax, headquartered in the US.
In August 2020, the 2 firms introduced an settlement beneath which Novavax had given SII the licence to manufacture and provide the vaccine in low- and middle-income nations.
(With IANS Inputs)
ALSO READ | Govt planning to carry extra inhabitants teams beneath COVID-19 vaccination drive: Harsh Vardhan
ALSO READ | HC asks Serum Institute, Bharat Biotech to disclose capability to manufacture COVID-19 vaccines
